The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study

Table 3 Hazard ratios (HR) for prevalent cases

	HR	[95% CI]
Cox model for CML cases diagnosed before February 1, 2002
Survived period
Post-TKI vs. Pre-TKI	0.66	0.36	1.20
Sex
F vs. M	0.53	0.30	0.94
Age at diagnosis
65–74 yrs vs. < 65 yrs	1.63	0.90	2.96
> 74 yrs vs. < 65 yrs	6.14	3.12	12.08
Residency
Mountainous vs. non-mountainous	1.20	0.55	2.59
Cox model for cases diagnosed before February 1, 2002 stratified by age at diagnosis
Age at diagnosis < 65 years
Post-TKI vs. Pre-TKI	0.33	0.13	0.87
Age at diagnosis 65–74 years
Post-TKI vs. Pre-TKI	0.68	0.23	2.02
Age at diagnosis > 74 years
Post-TKI vs. Pre-TKI	0.80	0.23	2.75

Cases diagnosed before TKI introduction. Effect of TKI introduction on prevalent cases. Hazard ratios for survival period pre-TKI and post-TKI introduction, calculated using Cox regression models adjusted for sex, age at diagnosis, residency (mountainous or non-mountainous area). Interactions between each covariate and exposure variable were assessed. A Cox regression model stratified by age at diagnosis and adjusted for sex and for residency was also performed

ISSN: 1471-2407